The first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years is now available in the United States.
SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. According to its maker, Sebela Pharmaceuticals, the tablets offer a safe and effective alternative to liquid colonoscopy preparations.
National guidelines recommend that adults at average risk begin screening for colorectal cancer at age 45.
“Alternative colonoscopy preparations, like SUTAB, can play an important role in encouraging more patients to get screened for colorectal cancer,” said Alan Cooke, President and CEO of Sebela Pharmaceuticals. “With the introduction of SUTAB tablets, we hope to take yet another important step toward removing some of the burden often associated with the preparation process – allowing more patients to feel confident in their choice to undergo a colonoscopy.”
The FDA approved SUTAB on November 10, 2020. The approval was based on positive Phase 3 clinical trials, which evaluated the safety and efficacy of SUTAB compared to FDA-approved preparations in 941 patients, including a traditional polyethylene glycol and ascorbate preparation (PEG-EA) for bowel cleansing prior to a colonoscopy.
A high rate of cleaning success was seen with SUTAB (92.4%), which demonstrated non-inferiority to PEG-EA (89.3%). Likewise, the percentage of patients rating their overall experience with SUTAB as “excellent” or “good” was higher than those rating PEG-EA (71.6% vs. 59.8%, respectively). For a future colonoscopy, 78% of patients said they would request SUTAB again.
SUTAB is now available by prescription in the U.S. To learn more, visit www.SUTAB.com.
SUTAB was developed by Braintree, the makers of SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution for adults—the market leader in branded colonoscopy preparations. Braintree, a leader in gastroenterology, is part of Sebela Pharmaceuticals.
Initiative aims to reduce stigma and educate about screening choices, as the Colorectal Cancer Alliance launches a health equity fund to decrease disparities.
On the horizon are blood tests that have shown the ability to detect a variety of cancers including colorectal and rare cancers. Though these tests are still in development and are not yet approved by the FDA, clinical trials have shown impressive results.
In February of 2022, John and Mary experienced the unimaginable. Their 36-year-old son, Jonathan, died of stage IV colon cancer. Though Jonathan had been dealing with ulcerative colitis from the time he was twelve, no one would have predicted this outcome twenty-four years later.